亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

武漢楷倫化學(xué)新材料有限公司銷售部  

埃索美拉唑鈉和埃索美拉唑,埃索美拉唑鎂,比馬前列素,普樂沙福及其中間體,普拉格雷

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:吳桐
  • 電話:027-88395796
  • 郵件:kailunchem@126.com
  • 傳真:027-88735683
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 鹽酸決奈達(dá)隆141625-93-6
鹽酸決奈達(dá)隆141625-93-6
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 湖北武漢市付款后3天內(nèi)
過期 長(zhǎng)期有效
更新 2014-05-29 14:27
 
詳細(xì)信息
鹽酸決奈達(dá)隆
英文名:Dronedarone Hydrochloride
中文化學(xué)名:N-[2-丁基-3-[4-[3-(二丁基氨基)丙氧基]苯甲酰基]-5-苯并呋喃基]甲磺酰胺鹽酸鹽
CAS:141625-93-6
分子式:C31H44N2O5S.HCL
分子量:593.22
結(jié)構(gòu)式:

用途:抗心律失常藥物
質(zhì)量標(biāo)準(zhǔn):企業(yè)標(biāo)準(zhǔn)
©2025 武漢楷倫化學(xué)新材料有限公司銷售部 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:9997  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |